Monday's top analyst upgrades, downgrades and initiations include Abbott Labs, Bluebird Bio, Chipotle, Eli Lilly, Ferrari and Wells Fargo.
Despite the howling from political candidates trying to make the top drug-makers their whipping boy in populist campaign efforts, the need and demand for pharmaceuticals will only continue. This is especially the case…
Friday's top analyst upgrades, downgrades and initiations include Abbott Labs, BioMarin Pharmaceutical, CBS, Cisco, GameStop, Petrobras, Sirius XM, SunPower and Yelp.
24/7 Wall St. screened the Merrill Lynch research universe for pharmaceutical stocks paying solid dividends that are rated Buy, and found four outstanding companies.
Wednesday's top analyst upgrades, downgrades and initiations include Adobe Systems, FireEye, Lululemon Athletica, Nu Skin, Rio Tinto, Tesla Motors and BHP Billiton.
A new report from Deutsche Bank makes the case that the selling in health care stocks is way overdone, and the proverbial baby is being tossed out with the bath water.
One positive from the hammering the pharmaceutical stocks have taken is the Merrill Lynch analysts say investors have been given a golden opportunity to buy the top companies at much better prices.
24/7 Wall St. screened the Merrill Lynch health care universe and found four pharmaceutical stocks rated Buy with outstanding short-term and long-term potential.
Earnings season is hitting its stride next week, and the health care sector, the biotech stocks in particular, have been on a roll for the past 12 months.
Generic drug maker Mylan has proposed to acquire rival Perrigo for $205 per share in cash and stock.
Mylan has announced that it will have a 35 million share secondary offering. At Tuesday's closing price of $59.35, the offering would be valued at $2.08 billion.
Friday's top analyst upgrades, downgrades and initiations include Cameron International, Dollar General, Genworth Financial, Groupon, SunPower, Visa and Yahoo.
The following companies were featured in a new Leerink report on understand testing trends for sexually transmitted diseases.
Here are five stocks that Jefferies highlights in its research report that have catalysts that could be important this week.
The U.S. Treasury has finally made its proposed effort to deal with the waves of corporate tax inversions that have created such a stir of late.
